Bristol-Myers shares slide on immunotherapy setback – Financial Times
Financial Times |
Bristol-Myers shares slide on immunotherapy setback
Financial Times Bristol-Myers was a pioneer of checkpoint inhibitors, a type of immunotherapy that turns the body's immune system into a weapon against tumours — but the pharmaceuticals group shocked investors last year when its drug, Opdivo, flunked a large clinical … Bristol-Myers Squibb, Where Art Thou? Not in First-Line Lung Cancer Immunotherapy, Sadly Bristol-Myers Dives On Opdivo Lung Cancer Setback; Merck Jumps Bristol won''t seek faster Opdivo/Yervoy lung cancer approval |
